EA201391304A1 - 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке - Google Patents

2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке

Info

Publication number
EA201391304A1
EA201391304A1 EA201391304A EA201391304A EA201391304A1 EA 201391304 A1 EA201391304 A1 EA 201391304A1 EA 201391304 A EA201391304 A EA 201391304A EA 201391304 A EA201391304 A EA 201391304A EA 201391304 A1 EA201391304 A1 EA 201391304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrimidindiamines
substituted
discoid lupus
lupus erythematosus
cutaneous lupus
Prior art date
Application number
EA201391304A
Other languages
English (en)
Other versions
EA030249B1 (ru
Inventor
Дэниел Маджилави
Полли Пайн
Original Assignee
Райджел Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Райджел Фармасьютикалз, Инк. filed Critical Райджел Фармасьютикалз, Инк.
Publication of EA201391304A1 publication Critical patent/EA201391304A1/ru
Publication of EA030249B1 publication Critical patent/EA030249B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

Соединения I и II, а также их соли и фармацевтические композиции, содержащие их, являются применимыми для лечения заболеваний и/или расстройств кожи, таких как кожная волчанка, например острая кожная красная волчанка, подострая кожная красная волчанка или дискоидная красная волчанка. В некоторых вариантах осуществления соединения предоставляются в композициях для местного применения.
EA201391304A 2011-03-10 2012-03-09 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке EA030249B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451531P 2011-03-10 2011-03-10
PCT/US2012/028429 WO2012122452A1 (en) 2011-03-10 2012-03-09 2,4 substituted pyrimidinediamines for use in discoid lupus

Publications (2)

Publication Number Publication Date
EA201391304A1 true EA201391304A1 (ru) 2014-05-30
EA030249B1 EA030249B1 (ru) 2018-07-31

Family

ID=45922810

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391304A EA030249B1 (ru) 2011-03-10 2012-03-09 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке

Country Status (21)

Country Link
US (2) US8497279B2 (ru)
EP (1) EP2683385B1 (ru)
JP (1) JP6121917B2 (ru)
KR (1) KR101802011B1 (ru)
CN (1) CN103533938A (ru)
AU (1) AU2012225367B2 (ru)
BR (1) BR112013023052A2 (ru)
CA (1) CA2866460C (ru)
CY (1) CY1120860T1 (ru)
DK (1) DK2683385T3 (ru)
EA (1) EA030249B1 (ru)
ES (1) ES2686532T3 (ru)
HR (1) HRP20181286T1 (ru)
HU (1) HUE039486T2 (ru)
LT (1) LT2683385T (ru)
MX (1) MX343517B (ru)
PL (1) PL2683385T3 (ru)
PT (1) PT2683385T (ru)
RS (1) RS57672B1 (ru)
SI (1) SI2683385T1 (ru)
WO (1) WO2012122452A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2788028B1 (en) * 2011-12-08 2019-03-27 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
EP2895172B1 (en) * 2012-09-12 2019-02-06 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
CN107805212B (zh) * 2017-11-03 2021-08-20 宿迁德威化工股份有限公司 一种2-甲基-5-氨基苯磺酰胺的制备方法
WO2021113410A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS6069037A (ja) 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1948686A4 (en) 2005-10-26 2009-06-10 Stc Unm C-REACTIVE PROTEIN AND ITS USE FOR THE TREATMENT OF SYSTEMIC LUPUSERYTHEMATODES AND RELATED SUFFERINGS
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos

Also Published As

Publication number Publication date
HUE039486T2 (hu) 2019-01-28
EA030249B1 (ru) 2018-07-31
RS57672B1 (sr) 2018-11-30
MX343517B (es) 2016-11-07
KR101802011B1 (ko) 2017-11-27
ES2686532T3 (es) 2018-10-18
BR112013023052A2 (pt) 2017-07-25
DK2683385T3 (en) 2018-09-17
PT2683385T (pt) 2018-10-19
US8497279B2 (en) 2013-07-30
SI2683385T1 (sl) 2018-11-30
US20120232106A1 (en) 2012-09-13
KR20140025377A (ko) 2014-03-04
WO2012122452A1 (en) 2012-09-13
US20130274277A1 (en) 2013-10-17
CN103533938A (zh) 2014-01-22
AU2012225367B2 (en) 2017-05-25
EP2683385B1 (en) 2018-06-06
EP2683385A1 (en) 2014-01-15
JP6121917B2 (ja) 2017-04-26
LT2683385T (lt) 2018-10-25
CY1120860T1 (el) 2019-12-11
MX2013010308A (es) 2013-12-02
CA2866460C (en) 2021-03-09
AU2012225367A1 (en) 2013-10-24
JP2014507480A (ja) 2014-03-27
CA2866460A1 (en) 2012-09-13
PL2683385T3 (pl) 2018-12-31
HRP20181286T1 (hr) 2018-10-05

Similar Documents

Publication Publication Date Title
EA201890641A3 (ru) Стимуляторы sgc
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590748A1 (ru) Противовирусные соединения против rsv
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015004721A (es) Compuestos de benceno sustituidos.
EA201391106A1 (ru) Новые гетероциклические производные
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
MX2013011922A (es) Compuestos de benceno substituido.
MA33939B1 (fr) 5-alcynyl-pyrimidines
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
DOP2015000170A (es) Compuestos químicos
CY1120860T1 (el) 2,4 υποκατεστημενες πυριμιδινδιαμινες για χρηση στον δισκοειδη λυκο
EA201590562A1 (ru) Бензамиды
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
EA201600434A1 (ru) Применение производных бензимидазолпролина
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
BR112015004306A2 (pt) fluorometil-substituído pirrol carboxamidas
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU